Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NV 103

Next Previous
Drug Profile

NV 103

Alternative Names: anti-CD99 TNS (CD99-TNS/Ir); Antibody-conjugated irinotecan liposomal nanoparticle - NanoValent Pharmaceuticals; CD99/Irinotecan nanoparticles; NV-103

Latest Information Update: 02 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NanoValent Pharmaceuticals
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ewing's sarcoma; Glioblastoma; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 02 Jul 2025 Preclinical development in Ewing's Sarcoma is underway in USA (Parenteral) (NanoValent Pharmaceuticals pipeline, June 2025)
  • 25 Apr 2025 Pharmacokinetics, pharmacodynamics and adverse events data from preclinical trials in Glioblastoma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 28 Jul 2024 No recent reports of development identified for preclinical development in Ewing's Sarcoma in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top